Business Wire

CA-NEXON-AMERICA

16.1.2020 15:02:15 CET | Business Wire | Press release

Share
Legendary Hero “Shade” Joins the Fray in Massive MapleStory M Content Update

MapleStory M , the free-to-play, massively multiplayer online mobile game for iOS and Android , is ringing in the new year with its biggest update yet - the introduction of the legendary Hero Shade with a variety of limited-time events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005227/en/

One of the most celebrated Heroes in Maple World, Shade is one of Six Heroes ending the sinister reign of MapleStory’s biggest antagonist, the Black Mage. The last Hero to be added to the MapleStory M universe, Shade is classified as a Pirate with a powerful force, using primary and secondary weapons of Knuckles and Fox Marbles to conquer enemies. Now reborn and, with the spirit world at his fingertips, he is investigating claims of the Black Mage’s return.

The update delivers an array of events to celebrate the new Hero Shade as well as Lunar New Year! Starting today, exciting level-up events will be available including:

  • Shade Growth Support Event: Until February 24, players who reach a certain level will receive additional in-game items useful for a specific character’s level-up.
  • Shade Burning Event: Any new Shade character can be leveled-up by three levels for every level up within level 3 to 100 until February 10.
  • Shade Celebratory Log-in Reward Event: Players logging-in from today through January 22 will receive a special gift to help their character level up once per account.
  • Heroes M Events: Through February 11, four different types of events are going to be held in honor of the Six legendary Heroes. Any characters or players with those Six Heroes will be rewarded with items to help boost experience as well as obtain additional stat options for their characters.

Along with the level-up events, there’s a bevy of Lunar New Year-themed events including:

  • Lunar New Year 7 Day Attendance Event: Between January 20 and February 3, participating players who log-in will claim attendance rewards for items that give their characters experience points.
  • Lunar New Year Achievement Event: Starting January 20 and ending February 3, players collect unique coins to earn rewards including an item that can assist with Starforce Reinforcement, Character Decorate item, and EXP Boost item.

To learn more about MapleStory M, visit the Google Play or App Store page and follow @PlayMapleM on Twitter for the latest updates.

Assets :

Social Media: Twitch / Facebook / Twitter / YouTube / Discord

About MapleStory M smarturl.it/110rng

MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the epic franchise. Available in 140 countries and 9 languages, MapleStory M quickly reached 10 million downloads within 100 days after global launch.

About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/

Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) with more than 80 live games operated across more than 190 countries, is a global leader in online games. Nexon America introduced micro-transactions and the free-to-play business model in the Western market and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.

Social Media:

https://www.facebook.com/PlayMapleM

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye